Chinese biotech Innovent Biologics is reportedly considering a $200 million IPO later this year that could take place in the U.S.

Gottlieb talked up the prospect of releasing redacted CRLs in his confirmation hearings but has now watered down his interest in the idea.

Celgene is lining up another deal for CAR-T biotech Juno Therapeutics, according to several media reports.

The pact sets Merck up to work with researchers at CRUK’s unit at the ICR on three preclinical oncology projects.

AveXis is expanding trials of its gene therapy for children with spinal muscular atrophy (SMA) as it plays catch-up with Biogen and Ionis.

The biotech indicated ubenimex is for the chop in PAH after a phase 2 trial in the indication failed to find a hint of efficacy. 

The €8.7 million series B will support studies targeting two bacterial infections and the creation of a drug manufacturing unit.

Describing a country as a ‘shithole’ isn’t going to endear you to anyone, but President Trump’s latest alleged outburst has struck a nerve with one particular…

Tyagi joins Hikma with a brief to stimulate noninjectable R&D activity at a time when the company's generic drug unit is suffering.